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Abstract
Adult bone marrow derived mesenchymal stem cells offer the potential to open a new frontier in
medicine. Regenerative medicine aims to replace effete cells in a broad range of conditions
associated with damaged cartilage, bone, muscle, tendon and ligament. However the normal
process of immune rejection of mismatched allogeneic tissue would appear to prevent the
realisation of such ambitions. In fact mesenchymal stem cells avoid allogeneic rejection in humans
and in animal models. These finding are supported by in vitro co-culture studies. Three broad
mechanisms contribute to this effect. Firstly, mesenchymal stem cells are hypoimmunogenic, often
lacking MHC-II and costimulatory molecule expression. Secondly, these stem cells prevent T cell
responses indirectly through modulation of dendritic cells and directly by disrupting NK as well as
CD8+ and CD4+ T cell function. Thirdly, mesenchymal stem cells induce a suppressive local
microenvironment through the production of prostaglandins and interleukin-10 as well as by the
expression of indoleamine 2,3,-dioxygenase, which depletes the local milieu of tryptophan.
Comparison is made to maternal tolerance of the fetal allograft, and contrasted with the immune
evasion mechanisms of tumor cells. Mesenchymal stem cells are a highly regulated self-renewing
population of cells with potent mechanisms to avoid allogeneic rejection.
Review
Introduction: What are Stem Cells?
The term "stem cell" can be applied to a remarkably
diverse group of cells. These cells, regardless of their
source, share two characteristic properties. Firstly, they
have the capacity for prolonged or unlimited self-renewal
under controlled conditions, and secondly they retain the
potential to differentiate into a variety of more specialized
cell types [1,2]. The stem cells that arise during the first
days of mammalian embryonic development are pluripo-
tent and are referred to as embryonic stem (ES) cells.
These are usually derived from the inner cell mass of the
pre-implantation embryo, at the blastocyst stage[3]. How-
ever stem cells are not confined to tissues of early develop-
ment, but can also be found at various sites in the adult
mammal. Adult stem cells are more differentiated then ES
cells but can still give rise to specialized lineages[1,2]. The
best-described populations to date are the hematopoietic
stem cells (HSC) of the bone marrow that can generate
various blood cells[4]. However the bone marrow also
contains a population of mesenchymal stem cells (MSC)
[1,2]. These cells, first characterized by Friedenstein and
colleagues more than thirty years ago, are multipotent
cells capable of differentiating into several lineages
including; cartilage, bone, muscle, tendon, ligament and
adipose tissue[2,5,6]. In their undifferentiated state, MSC
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There are no cell surface markers that specifically and
uniquely identify MSC, and their characterization in the
literature lacks consistency. The diversity of characteristics
associated with MSC can be explained by differences in
tissue origin, isolation methods and culture conditions
between laboratories, in addition there appear to be
strain-to-strain differences in murine derived MSC[2,7-9].
Whilst there is an obvious need for standardization
between research groups, some consensus can be found
among the conflicting data. In broad terms, MSC
expanded in vitro do not express the hematopoietic or
endothelial surface markers CD11b, CD14, CD31, CD34
or CD45 but stain positive for CD29, CD44, CD73,
CD105, CD106 and CD166 [2,5,10]. The non-embryonic
source of this population, the reduced likelihood of neo-
plasia, and the more limited differentiation potential,
have made these cells attractive candidates for application
in cell based therapies usually termed "regenerative med-
icine"[2]. There is one confounding influence on this
approach; whilst self derived MSC pose few immunologi-
cal problems, in practice regenerative medicine is likely to
rely on mismatched (allogeneic) cells to repair or replace
damaged tissue. Normally, allogeneic cells are deleted by
host immune responses. The major surprise to Immunol-
ogists working in this field have been findings that suggest
that MSC do not obey the normal "rules" of allogeneic
rejection. This review will survey recent data, which con-
vincingly indicate the mechanisms by which MSC escape
the normal process of alloantigen recognition.
MSC evade allorejection
The major limit to solid organ graft survival is T cell recog-
nition by the recipient of alloantigen (dominated by, but
not confined to MHC/HLA antigens)[11]. There are two
mechanisms mediating this powerful rejection response;
"direct" recognition, involving recognition by recipient
CD8+ or CD4+ T cells of donor MHC class I and class II
molecules; and "indirect" mechanisms involving recogni-
tion of peptides from the allogeneic tissue[11]. Recipient
antigen presenting cells (APC) such as dendritic cells
(DC) process alloantigen into peptides and present these
to naive T cells on self-MHC molecules [12]. However
there are notable exceptions to these allorejection proc-
esses; the fetal allograft evades rejection by the mother
through a complex series of actions (reviewed in[13]),
similarly tissue which has limited lymphatic drainage is
less prone to allorejection[14]. Interestingly tumor cells,
whilst not allogeneic, are in many cases both "altered-self"
and immunogenic but often actively modulate immune
responsiveness to evade immune surveillance[15]. Thus
mechanisms of tumor evasion of the immune system may
provide insight into how allogeneic MSC are tolerated by
the mismatched host.
There is supporting evidence for the use of allogeneic MSC
from both in vitro and in vivo studies that show MSC
avoid normal alloresponses. A small number of in- vivo
studies suggest that MSC play a role in enabling alloanti-
gen tolerance. Koc et al, showed no evidence of alloreac-
tive T cells and no incidence of graft v host disease when
allogeneic MSC were infused into patients with Hurler's
syndrome or metachromatic leukodystrophy[16]. In a
previous study by the same group, autologous culture-
expanded MSC were infused to breast cancer patients to
investigate whether MSC would enhance the engraftment
of peripheral blood stem cells after myeloablative therapy
[17]. Results showed rapid hematopoietic recovery and no
signs of toxicity from MSC infusion[17]. Horwitz and col-
leagues, reported that donor MSC contributed to bone
remodelling after allogeneic stem cell transplantation in
three children with osteogenesis imperfecta (OI)[18], a
rare genetic disorder of type I collagen. This is supported
by data from Bartholomew et al who showed that in-vivo
administration of allogeneic MSC prolonged 3rd party
skin graft survival in animal models[19]. Furthermore,
Saito et al, demonstrated that MSC undergoing differenti-
ation to a cardiac phenotype were tolerated in a xenoge-
neic environment, retaining their ability to be recruited to
the injured myocardium[20]. More recent work by Aggar-
wal and Pittenger supported the feasibility of MSC-trans-
plantation showing that MSC altered the phenotypes of
specific immune cell subtypes thereby creating a
tolerogenic environment[21]. These reports suggest that
transplantation of MSC could be beneficial in patients
with various disorders requiring tissue regeneration, and
Human mesenchymal stem cells (MSC) are spindle shaped, fibroblast-like ellsFigure 1
Human mesenchymal stem cells (MSC) are spindle shaped, 
fibroblast-like cells. Original magnification × 100, phase-con-
trast light microscopy, scale bar represents 50 µm.Page 2 of 11
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MSC by recipients.
Data supporting the contention that MSC avoid alloge-
neic responses has also come from a large body of in vitro
experiments, usually involving co-culture or mixed lym-
phocyte reactions (MLR). Evidence from these studies
indicate that the use of mismatched MSC does not pro-
voke a proliferative T cell response in allogeneic MLR, thus
suggesting an immunosuppressive role for MSC[19,22-
26]. Le Blanc et al, showed that MSC failed to elicit prolif-
eration of allogeneic lymphocytes[27]. Additionally, they
demonstrated that MSC remained immunosuppressive
even after IFN-γ stimulation[27]. Evidence from Krampera
et al confirms these findings, they showed that murine
MSC lack MHC class II and inhibited T cell prolifera-
tion[25]. Tse et al, also showed that human MSC fail to
elicit allogeneic T cell response in a MLR even when MHC
class II was upregulated[28]. Consistent with these stud-
ies, Bartholomew et al showed that allogeneic baboon
MSC suppressed the proliferative activity of lymphocytes
in vitro and prolonged graft survival[19]. These findings
support the view that MSC can be transplanted between
MHC-incompatible individuals. Although these data
show that successful use of allogeneic MSC in regenerative
therapy is possible, such approaches are unlikely to be
broadly acceptable until it is understood why MSC are not
rejected. This question has been the subject of intense
recent study and three candidate mechanisms are emerg-
ing. MSC appear to evade allogeneic rejection by a) being
hypoimmunogenic; b) modulating T cell phenotype and
c) creating an immunosuppressive local milieu. These
mechanisms are inter-related and will involve cell contact
dependent and independent interactions. The challenge
facing the field is to unravel the contribution of these
diverse interactions.
MSC are hypoimmunogenic
There is controversy surrounding the cell surface expres-
sion of MHC alloantigens by MSC. Although conflicting
evidence exists, most studies describe human MSC as
MHC class I positive and MHC class II negative (Fig 2).
The data conflicting with these findings may represent dif-
ferent stem cell lineages or be the result of the recently
described process of cell-cell transfer [29-31]. The expres-
sion of MHC class I by MSC is important because expres-
sion protects MSC from certain NK cell mechanisms of
deletion. For instance, a major function of NK and NK-
like cells is to kill tumor cells that have downregulated
class I [32]. HLA-G is an MHC-like protein that is known
to protect the fetal allograft against NK mediated rejec-
tion[33,34]. This protein has been shown to bind to the
two major inhibitory NK receptors, KIR1 and KIR2, and to
inhibit NK killing [35-37]. However no studies of HLA-G
expression by MSC have been reported to date.
As MHC class II proteins are potent alloantigens, the
expression by MSC is another important factor. Again
there is some controversy over expression, which may be
explained by the diversity of models described above.
However there are widespread observations that under
non-inflammatory conditions, human MSC are MHC-II
Human MSC cultured according to [106, 107] are A) MHC-I positive (HLA-A,B,C, antibo y W6/32-FITC), B) MHC class Inegative ( LA-DR, antibody LN-3-PE); C) CD14 negative (antibody MEM-18-FITC), D) CD86 negative (antibody IT2.2-PE); an E) D40L/ CD154 (a tib dy 24-31-FITC), F)CD95L (FasL) negative (antibody NOK-1-PE)Fi ure 2
Human MSC cultured according to [106, 107] are A) MHC-I 
positive (HLA-A,B,C, antibody W6/32-FITC), B) MHC class II 
negative (HLA-DR, antibody LN-3-PE); C) CD14 negative 
(antibody MEM-18-FITC), D) CD86 negative (antibody IT2.2-
PE); and E) CD40L/ CD154 (antibody 24-31-FITC), F) 
CD95L (FasL) negative (antibody NOK-1-PE). Isotype 
matched control antibody labelling are shown as unshaded 
plots, FITC conjugates are shown in blue, PE conjugates 
shown in pink. Flow cytometry performed according to 
methods previously described [108-110].Page 3 of 11
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immunogenicity through the control of alloantigen
expression [38-40]. The absence of MHC class II gives
MSC the potential to escape recognition by alloreactive
CD4+ T cells. In addition to being MHC II negative, MSC
do not appear to express the co-stimulatory molecules
CD40, CD40L, CD80 or CD86 required for effector T cell
induction[28,39]. The absence of co-stimulatory mole-
cules is a significant observation. It implies that any resid-
ual engagement of the T cell receptor on Th cells would
result in anergy and contribute to tolerance rather than
allogeneic responses. Although this is a comforting sce-
nario, based largely on in vitro studies, it cannot fully
explain the evasion of alloreactivity demonstrated by
MSC. Experiments involving allogeneic co-cultures or
MLR have demonstrated that both cell-cell contact and
action by soluble factors contribute to the immunomod-
ulatory function of MSC[25,41-43]. Thus it is likely that
evasion of alloreactivity is a result of both MSC hypoim-
munogenicity, modulation of T cell immune induction
and the creation of a suppressive milieu around MSC.
Although the mechanisms governing the suppressive
effect are not fully understood, several studies have given
indicators to the processes involved.
MSC interfere with DC maturation and function
Dendritic cells (DC) are the most influential APC, playing
a key role in directing cellular and humoral immune
responses against self and non-self antigens [44]. DC con-
tribute to the establishment of tolerance, especially in the
periphery[45]. Immature DC are not fully differentiated
to carry out their known roles as inducers of immu-
nity[45]. Despite this, immature DC circulate through tis-
sues and the lymph system, capturing self and non-self
antigens[45]. Immature DC that are loaded with antigen
can silence T cells by deletion or by expanding regulatory
T cell populations[45,46]. It has long been believed that
this process contributes to graft survival during transplan-
tation [14]. The capacity of DC to induce peripheral toler-
ance is a potential mechanism by which MSC could
manipulate immunity in order to escape T cell recogni-
tion. Thus MSC could prevent normal allogeneic
responses either through modulation of DC function or
by direct effects on T cells. Indications from different stud-
ies encourage this hypothesis. Zhang et al [24] provides
evidence that MSC interfere with DC maturation. Co-cul-
ture experiments showed that MSC down-regulate CD1a,
CD40, CD80, CD86, and HLA-DR expression during DC
maturation[24]. This is also shown by Beyth et al. [42],
who suggest that human MSC converted APC into an
inhibitory or suppressor phenotype via cell-to-cell con-
tact, thus locking DC into a semi-mature state and thereby
inducing peripheral tolerance. Their findings also show
reduced IFN-γ, IL-12 and TNF-α in human MSC/mono-
cyte co-culture [42]. Similarly Jiang et al reported that
MSC maintain DC in an immature state[26] and show
that MSC inhibit up regulation of IL-12p70 [26]. These
results suggest that MSC mediate allogeneic tolerance by
directing APC towards a suppressor or inhibitory pheno-
type that results in an attenuated or regulatory T cell
response.
MSC modulate CD4+ T cell responses
Evidence has emerged that MSC interact directly with T
cells to suppress alloreativity[25]. Krampera et al showed
that MSC impair T cell contact with APC in a non-cognate
but transient fashion[25]. This supported work from Bar-
tholomew et al showing that the addition of IL-2 to MLR/
MSC co-cultures reduced MSC suppression and restored T
cell proliferation[19]. Taken together, these results
strongly support a role for either a direct (T cell pheno-
type) or indirect (DC phenotype) mechanism of immune
modulation directed by MSC.
MSC modulation of CD4+ T cell responses is more exten-
sive than the straightforward effect described above. The
regular process of antigen specific CD4+ T cell induction
requires antigen capture and processing by DC (or other
amenable cells), followed by a process of maturation and
trafficking to local lymph nodes[14,47-49]. There is evi-
dence that MSC prevent normal allogeneic responses by
directing CD4+ T cells to a suppressive or counter-regula-
tory phenotype[46,50]. Di Nicola et al, showed that MSC
strongly suppressed CD4+ (and CD8+) T cells in
MLR[43], findings supported by Tse et al, who showed
that MSC suppress the proliferation of T-cell subsets[28].
Studies of T cell differentiation have shown that in the
presence of human MSC, Th1 cell secretion of IFN-γ
dropped by 50% compared to cultures without MSC.
Conversely, effector T cells undergoing Th2 differentiation
when co-cultured with human MSC showed a significant
increase in IL-4 production compared to controls[21].
These findings suggest that MSC exert a counter regula-
tory, anti-inflammatory role by directing cytokine-medi-
ated immunity[21].
A strategy of regulation and deletion of specific T cells is
an effective control against unwanted immune respon-
siveness especially after transplantion[51]. Consequently,
enormous interest has focused on the possibility of Treg
cells as a marker for T cell tolerance during transplanta-
tion. Treg can act directly on other T cells or indirectly
through APC[46]. Aggrawal et al, demonstrated that
CD4+ CD25+ T reg populations increased significantly in
MLR when MSC were present compared to controls[21].
However, data exists showing that human MSC-mediated
inhibition is not suppressed by removing T reg cells from
co-cultures [25,42]. Nevertheless a role for these cells can
not be excluded, it is possible that an incomplete replica-
tion of the suppressive microenvironment in vitro orPage 4 of 11
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these studies do not fully explore the potential role of sup-
pressive or regulatory T cells in promoting MSC tolerance.
MSC influence control over cell division cycle pathways in
cells of immunological relevance. Glennie et al have
shown that T cells stimulated in co-cultures with MSC
exhibit an extensive inhibition of cyclin D2 and upregula-
tion of the cyclin dependent kinase inhibitor p27kip1 [52].
As T cell inhibition could not be reversed, these cells were
not interpreted as anergic in the classical sense. The
authors suggest that MSC are most likely inducing the
alternative condition of divisional arrest anergy in T cells,
an occurrence usually associated with CTLA-4 signal-
ling[53]. In addition, removal of MSC from the system
only restored IFN-γ production but not T cell prolifera-
tion[52]. This suggests that MSC induce a condition simi-
lar to split anergy[54] or split tolerance[55,56]. The key
point is that this work demonstrates that MSC exert veto
effects on T cells and it is significant in demonstrating that
the mechanisms inducing MSC tolerance are not confined
to patterns of cytokine secretion but extend to direct mod-
ulation of T cell division.
MSC modulate CD8+ T cell and NK cell activity
The impact of MSC on CD8+ CTL and NK cells has also
been addressed. CTL can lyse allogeneic cells after recog-
nition of cognate alloantigen, by the release of cytotoxic
effectors such as, perforins, serine esterases, IFN-γ and
TNF-α [57] whereas NK cells do not require antigen
processing[58]. Consequently both effector cells can oper-
ate in tandem, with NK cells providing a first line defence
killing target cells that escape CTL recognition or show
inadequate expression of self-MHC[58]. There is evidence
that MSC inhibit the formation of CTL and appear to
evade NK cell targeting mechanisms. Djouad et al showed
that CD8+ cells are suppressed by MSC in MLR[41]. Ras-
musson supported these findings and further showed that
NK cells in co-culture did not recognize MSC although
lytic capability was still present[59]. This effect appeared
to be mediated by soluble factors[50,59]. Thus MSC inter-
act and suppress cell-mediated immune responses directly
and through soluble factors. The targets for this suppres-
sion are DC, CD4+ Th, CD8+ CTL and NK cells; in effect
MSC silence each aspect of the cellular rejection process.
MSC secrete soluble factors to create an 
immunosuppressive milieu
The characterisation of cytokines produced by MSC is still
provisional and is hindered by the lack of standardisation
in isolation and culture conditions, which have given rise
to multiple findings and interpretations. It is evident that
MSC do not constitutively express IL-2, IL-3, IL-4 and IL-
5[60,61]. However some reports show that MSC do con-
stitutively express mRNA for cytokines such as interleukin
(IL)-6, -7, -8, -11, -12, -14, -15, -27, leukaemia inhibitory
factor, macrophage colony-stimulating factor, and stem
cell factor[62,63]. Some of these cytokines provide critical
cell-cell interactions and promote HSC differentiation,
however caution should be exercised before over inter-
preting these findings. Protein secretion does not always
mirror mRNA levels and most workers in the field would
adopt a more conservative profile of cytokine and growth
factor production by MSC.
Despite these caveats, certain MSC secreted products such
as Hepatocyte growth factor, (HGF) are likely to contrib-
ute to creating a local immunosuppressive environment.
HGF induces mitogenic and antiapoptotic activity in dif-
ferent systems [64-66] and has a well-characterized role in
wound repair [66-68], effects that are consistent with a
role for MSC in regenerative medicine. Although some
groups do not detect HGF in MSC co-cultures [41] more
reports suggest that HGF is constitutively expressed by
MSC [13,43,69,70]. Indications that MSC produce HGF
[13,43,69,70] encourage a role for these cells in tissue
repair [70]. Studies by Chunmeng et al, demonstrated that
rat dermal derived "multipotent" cells secrete HGF and
promote wound healing[68]. Interestingly, Azuma et al,
showed that HGF treatment prevents chronic allograft
nephropathy in rats[71]. Taken together these results sug-
gest that HGF may contribute to the ability of MSC to
avoid allorejection.
IL-10 has a well-documented role in T cell regulation and
in the promotion of a "regulatory" or suppressor pheno-
type. In our hands human MSC constitutively produce IL-
10 whereas Rasmusson et al and Beyth et al only detected
IL-10 in co-culture experiments [42,72]. In either case, IL-
10 is likely to be suppressing potential allo-responsive-
ness because it is a recognized growth factor for regulatory
T cells [73]. IL-10 can antagonize IL-12 during induction
of inflammatory immune responses [74-79]. This is sup-
ported by studies showing that MSC partially mediate
suppression through IL-10 secretion in MLR cul-
tures[42,72]. Similarly transforming growth factor (TGF)-
β1 also plays a role in T cell suppression. This cytokine as
well as IL-10 influences cell lineages broader than lym-
phocytes [74,80,81]. However constitutive expression of
TGF-β1 has not been detected from our own studies on
human MSC[13]. This is in line with Le Blanc who found
no difference in TGF-β1 concentration in co-cultures with
or without MSC [69]. In contrast Beyth et al showed that
TGF-β1 was secreted in media from co-cultures of human
MSC and immune cells but again co-culture did not aug-
ment TGF-β1 concentration[42]. Although a number of
studies suggest no role for TGF-β1 in evasion of allogeneic
responsiveness[42,69,72], it has been suggested that HGF
in combination with TGF-β promotes the allo-escaping
phenotype[43]. Di Nicola et al showed that neutralizingPage 5 of 11
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response in MLR, suggesting that these factors are at least
partially responsible[43].
MSC constitutively express the eicosanoid Prostaglandin E
(PGE)-2 [82]. This may be upregulated in co-cul-
ture[21,28] or downregulated on differentiation[82].
PGE-2 influences numerous immune functions including
suppression of B cell activation[83] and induction of reg-
ulatory T cells[84]. Although there is evidence for PGE-2
secretion by MSC, there is controversy surrounding a role
for PGE-2 as a mediator for suppression of alloresponses
in MLR. Studies from Tse, suggested that PGE-2 is not a
significant component of suppression[28]. Supporting
these findings Rasmusson et al showed that blocking PGE-
2 production did not restore allogeneic MLR responses
but did influence mitogen driven proliferation[72].
Although the present opinions are conflicting, it should
be highlighted that other possible prostaglandins and
eicosanoids could be influencing alloresponses[85]. Anal-
ysis of these other immunomodulatory molecules could
provide further clues as to how MSC escape the immune
system.
In contrast to immunosuppression through the secretion
of soluble factors, suppression may be mediated by with-
drawal of factors in the micro-environment necessary for
active immune responses. Indoleamine 2,3-dioxygenase
(IDO) is an enzyme that catabolizes L-Tryptophan,
thereby depleting an essential amino acid from the local
environment [86-89]. Recent evidence has shown that
this mechanism is exploited by the mammalian fetal allo-
graft to suppresses T cell activity and prevent rejection [86-
89]. Although not a soluble factor, the expression of IDO
may contribute to a tolergenic environment. This is of
great relevance and has obvious parallels with MSC. Mei-
sel et al showed that IDO is not constitutively expressed
by MSC but can be induced by IFN-γ[90], thereby inhibit-
ing allogeneic T cell responses by Tryptophan deple-
tion[90]. Other findings have suggested that IDO-
mediated tryptophan depletion inhibits allogeneic T-cell
responses by multiple pathways[91]. The discovery of this
mechanism, which shows parallels to the creation of a
"Tryptophan desert" at the materno-fetal interface[13],
provides a further feasible mechanism by which MSC
avoid alloreactivity. However, IDO expression is not
essential to the maintenance of tolerance against MSC. Tse
et al showed that an IDO inhibitor or supplementary
Tryptophan addition to MLR did not restore PBMC prolif-
eration [28].
MSC control surface marker expression to exhibit a
hypoimmunogenic or tolerogenic phenotype. MSC can
also modulate T cell induction directly or via DC and
secrete a battery of immunosuppressive factors. It is
apparent that the question facing the application of regen-
erative medicine is no longer "how do MSC escape allore-
activity?" but rather "what is the hierarchy of signals that
control immunosuppression?" In this regard, research
from other fields has been informative. We have previ-
ously proposed that maternal acceptance of the fetal allo-
graft provides indicators of how this process is
controlled[13]. However, insight could also come from
another avenue of inquiry. The mechanisms of tumor eva-
sion may reflect the survival mechanisms of MSC.
MSC avoidance of alloreactivity shows parallels to tumor 
evasion
Escape from immune surveillance is believed to be a pri-
mary feature of malignant disease in humans. The
immune effector response is sub-optimal because tumors
develop multifactorial strategies to escape immune dele-
tion[92,93]. These strategies may provide clues to how
MSC promote tolerogenic mechanisms during allogeneic
engraftment (Fig. 3). Modulation of tumor antigen
expression, particularly MHC class I and II is a particularly
common component of tumor immune evasion[93]. This
is often accompanied by poor or non-expression of co-
stimulatory molecules, which not only limits clonal
expansion of tumor-specific CD4+ T cells, but also hin-
ders the production of cytokines, and the development of
CTL[44,94,95]. Similarly MSC show no expression of co-
stimulatory molecules (Fig. 2) [28,39]. In addition to
reduced immunogenicity, tumor cells can directly modu-
late DC and T cell function. Studies from patients with
hepatocellular carcinoma showed that neoplasia induced
a defect of DC maturation[96]. This parallels findings by
Beyth et al [42] suggesting that human MSCs interfere
with normal APC maturation, thereby indirectly influenc-
ing T-cell activation. Freshly isolated tumor-infiltrating T
cells are usually inactive against autologous cancer cells
but can be reactivated in-vitro by the addition of IL-2[97].
Studies of MSC by Le Blanc et al showed striking parallels
to this form of suppression[69]. They suggest that MSC act
by preventing expression of CD25 (IL-2 receptor) thereby
limiting T cell activation[69]. Other work has shown that
exogenous IL-2 addition to co-cultures containing MSC
reversed the suppressive effect[19,69]. Similarly, antigen-
specific CD4+ CD25+ regulatory T cells also suppress
tumor-specific CD8 T cell cytotoxicity although this mech-
anism relies on TGF-β secretion by regulatory cells[98,99].
Tumors can suppress CD4+ T cell activity and CTL tumor
lysis directly through secretion of immunosuppressive
factors including TGF-β1 but also PGE-2, and IL-10. Van
der Pouw Kraan et al, showed that tumor-derived prostag-
landins increased the production of inhibitory cytokines
such as IL-10, while suppressing IL-12[100], which is nec-
essary for effective host-cell-mediated anti-tumor immune
response[75,93]. Likewise, TGF-β production has beenPage 6 of 11
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immune evasion. Intriguingly in this context it also inhib-
its CTL differentiation [101]. Although there is little evi-
dence that MSC secrete TGF-β1, the bone marrow is rich
in this cytokine, suggesting that MSC reside in a compart-
ment with immunosuppressive qualities.
Although there are striking parallels between MSC and
some tumor cells, it is not our contention that these cells
are directly related. Indeed there are distinct differences
between the populations (Table 1). The fundamental dif-
ference between the cell types resides in the control of cell
division and apoptosis, which are tightly regulated in
MSC but dysregulated in transformed cells. Furthermore,
it is well documented that some tumors exploit FasL
(CD95L) expression to facilitate immune escape [102-
104]. However, our own studies show that human MSC
do not express FasL (Fig 2) and although there is some evi-
dence from immortalized mini-pig derived MSC to indi-
cate a role for FasL in suppression[105], it seems that
direct induction of apoptotic deletion is not a factor
involved in MSC interaction with T cells in the broader lit-
erature. The parallels between neoplastic cells and MSC lie
in the expressed phenotypes rather than in any direct lin-
eage relation. It appears that MSC retain certain aspects of
the fetal allograft that promote tolerance, some of these
mechanisms may be reactivated in neoplasia, the key dif-
ference being that MSC perform these functions in an
ordered and controlled way whereas tumor cells do so in
a manner that by definition has escaped normal controls
on apoptosis or cell division.
Conclusion
Current research on the interaction between MSC and T
cells support the potential use of allogeneic MSC in regen-
erative medicine. Studies showing enhanced MSC engraft-
ment of bone, muscle, heart etc encourage the translation
of recent research into therapy. The future holds much
promise for the use of allogeneic MSC and whilst obsta-
cles exist, the potential for alloreactivity does not seem to
be a major problem. From the research standpoint, MSC
appear to use a surprising array of mechanisms to avoid
deletion by the host including hypoimmunogenicity,
modulation of DC and T cell function, as well as the crea-
tion of a suppressive microenvironment. The challenge is
now to unravel the timing and control of these mecha-
nisms in an inflammatory situation typical of the recipi-
ent patient.
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